Ask AI
ProCE Banner Activity

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

Podcast Episodes

In this episode, Eytan M. Stein, MD, and Eunice S. Wang, MD, explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care.

Released: July 25, 2025

Expiration: January 24, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Kura Oncology, Inc. and Syndax Pharmaceuticals, Inc.

Kura Oncology, Inc.

Syndax Pharmaceuticals, Inc.

Disclosure

Primary Author

Eytan M. Stein, MD: consultant/advisor/speaker: Syndax.

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Astellas, Blueprint, Daiichi Sankyo, Dark Blue, Dava Oncology, GlaxoSmithKline, Kite, Kura, Novartis, Qiagen, Rigel, Ryvu, Schrodinger, Servier, Stemline, Syndax, Pfizer, Takeda; data and safety monitoring: AbbVie.